A Nordic post-authorization safety cohort study assessing the Desloratadine exposure and incidence of Seizure
Latest Information Update: 12 Oct 2021
Price :
$35 *
At a glance
- Drugs Desloratadine (Primary)
- Indications Asthma; Chronic urticaria; Rhinitis
- Focus Adverse reactions
- Acronyms PASS
- 12 Oct 2021 New trial record
- 05 Oct 2021 Results published in the Drug Safety